Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 14,101–14,200 of 15,747
Stability and bifurcation dynamics of a fractional-order two-strain COVID-19 model
Thakur, P., Srivastava, K., Singh, V., & Srivastava, S. K. (2026) · Acta Universitatis Sapientiae Mathematica · doi:10.1007/s44426-026-00053-z
建部, 将., & 瀬尾, 龍. (2022) · Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo) · doi:10.3950/jibiinkotokeibu.125.3_243
Optic Neuritis Following COVID-19 Vaccination: Real-World Ophthalmic Presentation
Roy, M., & Shrotriya, C. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106322
Medical occurrence and safety of SARS-CoV-2 vaccination outside of the hospital setting
Ferrari, F., Sodi, F., Madotto, F., Carlesso, E., Florio, G., Pelliccia, M. R., Laquintana, D., Bisesti, A., Piatti, A., Letzgus, M., et al. (2024) · Internal and Emergency Medicine · doi:10.1007/s11739-024-03641-4
Infection Control, Prophylaxis, and Vaccinations in Hematopoietic Cell Transplantation Recipients
Malek, A. E., & Ariza‐Heredia, E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79833-4.00030-9 · Cited by 1
Immunological Changes in Pregnancy and Its Relation to COVID-19 Infection
Hamza, A. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90595-4.00006-6
RNA Therapy in Muscle Diseases
Lu, D., & Li, J. (2026) · Physiology · doi:10.5772/intechopen.1014065 · Cited by 1
Shou, Y., & Lou, J. (2024) · Journal of Applied Analysis & Computation · doi:10.11948/20230365
Divalent Metal Ions Boost Effect of Nucleic Acids Delivered by Cell- Penetrating Peptides
Maloverjan, M., Biswas, A., Padari, K., Abroi, A., Rebane, A., & Pooga, M. (2022) · European Peptide Symposium (EPS) · doi:10.17952/36eps/36eps.2022.117
Dedinská, I., Dadhania, D. M., Li, C., Hauser, N., Lamba, P., Lee, J. R., Muthukumar, T., & Suthanthiran, M. (2026) · medRxiv · doi:10.64898/2026.01.22.26344293
Guarnaccia, A. D., Sandoval, W. N., & Lill, J. R. (2025) · Wiley eBooks · doi:10.1002/9781394236145.ch1
Twenty-First-Century Medicine: Epidemiological, Personalized, or Postmodern?
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0013
Corrêa, T. D., Midega, T. D., Nawa, R. K., et al. (2025) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2025ao1060
EDUKASI DAN SOSIALISASI VAKSIN COVID-19 PUSKESMAS CITEUREUP, JAWA BARAT
Tuba, S., Widyati, W., Wardhani, B. W. K., Harahap, Y., & Simorangkir, T. P. H. (2022) · JMM (Jurnal Masyarakat Mandiri) · doi:10.31764/jmm.v6i1.6004
Abbad, A., Lerman, B., Ehrenhaus, J., Ojeda, D. S., Gleason, C., Singh, G., Khalil, Z., Gonzalez-Reiche, A. S., Srivastava, K., Fernández-Sesma, A., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.128018
Nguyen, H. B., Nguyen, T. H. M., Vo, T. H. N., Le, H. P., Vo, T. M. C., Nguyen, T. A. N., Tang, T., Nguyen, H. T., Dang, A. L., & Truong, Q. B. (2022) · The Open COVID Journal · doi:10.2174/26669587-v2-e221117-2022-20 · Cited by 1
Alves, K., Kotloff, K. L., McClelland, R. S., Hammershaimb, E. A., Kouassi, A., Plested, J. S., Kalkeri, R., Zhu, M., Cloney-Clark, S., Cai, Z., et al. (2025) · medRxiv · doi:10.1101/2025.04.09.25325550
Silva, M. D. J., Souza, J. D. S., da Hora, H. S., Santos, H. M., Hodel, K. V. S., Fonseca, L. M. D. S., Nunes, D. D. G., Murari, T. B., Moret, M. A., Santos, A. Á. B., et al. (2026) · Next Nanotechnology · doi:10.1016/j.nxnano.2026.100541 · Cited by 1
Ethnological aspects of COVID-19
Dhiman, P., & Bhatia, M. (2022) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902022e20975
Yoshinaga, Y., Ito, S., Oe, M., Manabu, A. B. E., SAITO, H., FUKAZAWA, Y., FUJIMORI, M., TANABE, K., & TAKAHASHI, C. (2024) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.e24002
Shahiwala, A. (2025) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2025.2563633 · Cited by 2
“…with adaptive clinical designs and rolling regulatory reviews facilitating iterative refinement. the test stage demonstrated >90% efficacy in large phase iii trials for both Pfizer-BioNtech’s comirnaty and moderna’s Spikevax, with pivotal publications confirming safety and effectiveness [92,93].”
Medical Evidence and Prediction
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0008
Ngan, M. T., Tran, G. T. H., Dang, A. H., Cao, P. T. B., Nguyen, T. T., Pham, H. T. L., Vu, T. T. T., Dong, H. V., & Huynh, T. M. L. (2022) · International Journal of Translational Medicine · doi:10.3390/ijtm3010001 · Cited by 1
Issues in Generalizing Results from Clinical Trials
Piantadosi, S. (2022) · Springer eBooks · doi:10.1007/978-3-319-52636-2_236
Singh, K., Grossman, S., & McMillan, K. G. (2021) · Dental Update · doi:10.12968/denu.2021.48.3.242
Quantum AI in mRNA Vaccine Development
Fakhoury, N., & Roosan, D. (2026) · Springer eBooks · doi:10.1007/978-3-032-19536-4_7
Draycheva, A., Millecam, J., & Caba, E. (2026) · International Journal of Toxicology · doi:10.1177/10915818261446630
COVID‐19 Vaccine Efficacy and the Evidence on BoostersPreprint
Black, B. S., & Thaw, D. B. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3987991
Tanislav, C., Ansari, T. E., Meyer, M., Müller, M., Grübener, R., Stein, T., Niemöller, U., Baaske, J., Kostev, K., Rolfs, A., et al. (2021) · Public Health · doi:10.1016/j.puhe.2021.06.003
Control of antigen presentation on MHC-I by a bacterial secretion systemPreprint
Leddy, O. K., McGinn, R. A., Allsup, B. L., Leone, M., Timms, P., Gutiérrez-González, M., Fahad, A. S., Milligan, R., García-Beltrán, W. F., DeKosky, B. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.19.689332 · Cited by 1
“Multiple vaccine platforms based on nucleic acids (mRNA vaccines and viral vectors) 55,56 have been clinically validated through their successful use against SARS-CoV-423 2 and now represent potential tools for cytosolic delivery of vaccine antigens in other disease areas.”
Rahmawati, R., & Salasanti, C. D. (2023) · Journal of Pharmacopolium · doi:10.36465/jop.v6i1.1100
“Efek samping ini umumnya ringan dan hilang dalam beberapa hari (Polack, et al., 2020; Baden, et al., 2021; Shimabukuro, Cole, & Su, 2021).”
BackgroundRNA-Based Therapies for Treating Monogenic Cardiomyopathies
Edwards, J. J., Edelson, J. B., & Rossano, J. W. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.12.040 · Cited by 1
Fan, C., Cohen, A. A., Dam, K.-M. A., Rorick, A. V., Fils, A.-C. I. P., Yang, Z., Gnanapragasam, P. N. P., Segovia, L. N., Huey‐Tubman, K. E., Moon, W. J., et al. (2025) · eLife · doi:10.7554/elife.108959 · Cited by 1
“Initial two-shot COVID-19 mRNA vaccination series became available in December 2020 after clinical studies demonstrated protection from severe disease after SARS- CoV-2 infection ( Polack et al., 2020 ; Baden et al., 2021 ).”
Assessment of Safety and Acceptance toward Covid-19 Vaccines: A cross-sectional Study in EgyptPreprint
Werida, R. H., Amralla, M. T., Bekhit, N. N., et al. (2025) · medRxiv · doi:10.1101/2025.10.28.25338945
The Systematic Research of The Comparison of Moderna Covid-19 Vaccine and Pfizer Covid-19 Vaccine
Wang, Q. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v45i.7384
Çınar, H. G., & Memiş, K. B. (2024) · Turkish Journal of Clinics and Laboratory · doi:10.18663/tjcl.1544956
Kurniawan, A., Koesnoe, S., Yunihastuti, E., et al. (2024) · Medicines · doi:10.3390/medicines11060012
Dong, S., Gong, F., Thomson, T., Cai, Y., Healy, L., Lu, R. X. Z., Zhou, Z., Xu, Y., Chen, J., Savguira, M., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03298-8 · Cited by 2
Kinganda-Lusamaki, E., Ortega‐Villa, A. M., Camara, D., Haidara, M. C., Blie, J., Coulibaly, N., Dewar, R. L., Kallon, K., Rehman, T., Sereti, I., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-69510-6
Daffini, R., Zecchini, F., Venneri, G., Malagola, M., Cattaneo, C. M., Calza, S., Caruso, A., Tucci, A., & Giagulli, C. (2026) · Vaccines · doi:10.3390/vaccines14050369 · Cited by 1
Bouton, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-80932-0.00031-8
SHIMASAKI, N. (2023) · Journal of Microorganism Control · doi:10.4265/jmc.28.4_177
Post effects associated with SARS-CoV-2 vaccination among health care workers in Pakistan
Furqan, W., Naeem, A., Usman, J., Ellahi, A., Ahmed, F., & Ahmed, A. R. (2022) · International Journal of Public Health Science (IJPHS) · doi:10.11591/ijphs.v11i2.21221 · Cited by 1
Siles, N., Schuler, M., Maguire, C. P., Amengor, D., Nguyen, A. W., Wilen, R. E., Rogers, J. E., Bazzi, S. A., Caslin, B., DiPasquale, C., et al. (2023) · medRxiv · doi:10.1101/2023.12.05.23299462
“18 In turn, anti-RBD antibodies, a subset of anti-S antibodies, are important for viral neutralization and inhibition of SARS-CoV-2 infection by blocking either the ACE2-RBD binding interactions or S-mediated membrane fusion.”
Singaravelu, S., Balu, R., Senthilkumar, C., & Jayaprakash, J. (2026) · Frontiers in Biomaterials Science · doi:10.3389/fbiom.2026.1912922
Isnardi, C. A., Pisoni, C. N., Cosatti, M. A., et al. (2025) · PubMed · doi:10.1097/rhu.0000000000002251
Khan, M. I., Sankaran, K. R., & Rahaman, S. O. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.23.707596
“…associate with negatively charged RNA under acidic conditions; structural phospholipids support membrane architecture and fusion; cholesterol regulates bilayer rigidity and stability; and PEG-lipids reduce aggregation and nonspecific interactions while prolonging systemic circulation (5-10).”
Evidence For COVID-19 Vaccine Deferred Dose 2 Boost TimingPreprint
Epperly, D. E. (2021) · SSRN Electronic Journal · doi:10.31219/osf.io/4p3bt · Cited by 2
Zeng, L., Pan, D., Huang, Y., Luo, D., Zhang, S., Lin, C., Lin, B., He, Y., Shi, X., Feng, S., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128699
Robust models of disease heterogeneity and control, with application to the SARS-CoV-2 epidemic
Johnson, K. D., Grass, A., Toneian, D., Beiglböck, M., & Polechová, J. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000412
Kurek, M. (2021) · Alergologia Polska - Polish Journal of Allergology · doi:10.5114/pja.2021.104654
Sana, A., Noor, S., Iqbal, K., et al. (2024) · Journal of Toxicological Studies · doi:10.59400/jts.v2i2.1372
“In December 2020, Pfizer–BioNTech, and Moderna were the first vaccines to get authorization for emergency use, and in phase III, clinical trials 95% efficacy was reported [9–11].”
BackgroundIssues in Generalizing Results from Clinical Trials
Piantadosi, S. (2022) · Springer eBooks · doi:10.1007/978-3-319-52677-5_236-1
Iwabuchi, R., Harada, M., Yamada, A., Aomura, D., Yamada, Y., Sonoda, K., Nakazawa, H., Sakai, K., Mizukami, E., Hashimoto, K., et al. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02348-8
“A previous study revealed that almost the entire healthy general population could obtain sufficient amounts of IgG antibodies and its clinical efficacy with two doses of the BNT162b2 mRNA COVID-19 Vaccine [1].”
BackgroundInfluentialEss, G., Lew, A. S., Tippett, A., Salazar, L. W., Choi, C., Castro, K. D., Taylor, E. G., Reese, O., Momin, H., Ciric, C. R., et al. (2025) · Vaccines · doi:10.3390/vaccines14010045
“Vaccine effectiveness (VE) against symptomatic COVID-19 was high for both vaccines in Phase III trials, at 95.0% for BNT162b2 and 94.1% for mRNA-1273 vaccine in SARS-CoV-2 naïve populations [9–11].”
InfluentialSinaei, R., Jafari, M., Karamozian, R., Pezeshki, S., Sinaei, R., Robati, F. K., Yeganeh, M. H., & Najafzadeh, M. J. (2023) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x19666230911094423
Pre-vaccine sentinel antibodies predict blunted vaccine responses
Song, L.-S., Park, J. G., Qiu, J., Murugan, V., mousavi, S., Hou, C.-W., Magee, D. M., Chen, Z., Chung, Y., Williams, S., et al. (2026) · Cell press blue · doi:10.1016/j.cpblue.2026.100088
Self-citationZhang, X., Araz, Ö. M., & Ertem, Z. (2025) · Health Systems · doi:10.1080/20476965.2025.2533783
“This model uses the data from antigen tests developed by Genalyte, Inc (Polack et al., 2020), given the test sensitivity is 96.1% (95%CI: 92.2–98.1%), and the specificity is 97.7% (95%CI: 96.4–98.5%).”
InfluentialAuroux, M., Laurent, B., Coste, B., Massy, E., Mercier, A., Durieu, I., Confavreux, C. B., Lega, J., Mainbourg, S., & Coury, F. (2022) · Revue du Rhumatisme · doi:10.1016/j.rhum.2022.07.002
“[7] Polack FP, Thomas SJ, Kitchin N, et al.”
Effect Measures and the Sufficient-Component Cause Model
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.005.0001
Bischof, M. L., Irrgang, P., Tenbusch, M., Keppler, O. T., & Wratil, P. R. (2026) · Medical Microbiology and Immunology · doi:10.1007/s00430-026-00878-y
COVID-19 mRNA vaccines: a prospective outlook from technological innovation to clinical practice
Ma, J., Chen, H., He, Y., Huang, Y., Duan, X., Liu, Q., Liu, Z., & Liu, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1757291 · Cited by 1
Gazzoni, F., Scherer, F. L., Soares, S. D. S., Piveta, M. N., & Pivetta, N. P. (2025) · Avaliação Revista da Avaliação da Educação Superior (Campinas) · doi:10.1590/1982-57652025v30id2836311 · Cited by 4
Self-inhibiting percolation and viral spreading in epithelial tissue
Xu, X., Nielsen, B. F., & Sneppen, K. (2024) · eLife · doi:10.7554/elife.94056 · Cited by 1
The Story of a Pandemic Foretold
Salgues, B., & Barnouin, J. (2022) · Wiley eBooks · doi:10.1002/9781394163755.ch2
COVID-19(„coronavirus disease 2019“)-Impfung
Gerloff, C. P., Berlit, P., & Klein, C. (2021) · DGNeurologie · doi:10.1007/s42451-021-00309-7
Na, Y. J., Choi, E. B., Kim, K., Kim, S., Moon, S. Y., Lee, Y.-K., & In, H. J. (2026) · Scientific Reports · doi:10.1038/s41598-026-45295-6
“The first-generation engineered spike S-2P, which includes two proline substitutions at positions 986 and 987 8–11 , has been incorporated into effective vaccines, such as mRNA-1273 and BNT162b2.”
SARS-CoV-2: To be or not to be vaccinated?
Beauchet, O. (2021) · Maturitas · doi:10.1016/j.maturitas.2021.01.006
Depleting S100A4 in Cancer-Associated Fibroblasts Reverses Cisplatin Resistance in Esophageal Cancer
Yu, H., Xu, M., Chen, R., Miao, L., Lü, Z., Lin, Y., Liu, Y., Zheng, W., Ji, T., & Yang, B. (2026) · ACS Applied Bio Materials · doi:10.1021/acsabm.6c00573
Cutaneous Reactions to COVID-19 mRNA Vaccines
Strahan, A. G., & Freeman, E. E. (2023) · Updates in clinical dermatology · doi:10.1007/978-3-031-45586-5_3
Koide, A., Panchenko, T., Wang, C., Thannickal, S. A., Romero, L. A., Teng, K. W., Li, F.-Z., Akkapeddi, P., Corrado, A. D., Caro, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.03.454782 · Cited by 1
“Accordingly, most current vaccines utilize the prefusion-stabilized form of spike as the antigen (Baden et al., 2021; Polack et al., 2020).”
BackgroundReinfection, recontamination and revaccination for SARS-CoV-2
Kullmann, T., & Drozgyik, A. (2022) · World Journal of Methodology · doi:10.5662/wjm.v12.i4.258 · Cited by 1
Klinik Faz Çalışmaları Devam Eden RNA Tabanlı COVID-19 Aşı Adayları
Al, L. İ. R., Sönmezer, M. Ç., & Ünal, S. (2021) · Flora the Journal of Infectious Diseases and Clinical Microbiology · doi:10.5578/flora.20219802
Self-citationRisk of SARS-CoV-2 infection and adverse outcomes among vaccinated patients with tuberculosis
Chang, R., Chen, S.-Y., Hsieh, T. Y. J., Chen, H.-Y., Wang, S., Hung, Y., & Wei, J. C.-C. (2025) · Public Health · doi:10.1016/j.puhe.2024.09.028
Liu, J., & Xu, G. (2024) · Rheumatology & autoimmunity · doi:10.1002/rai2.12126
POST VACCINATION COVID POSITIVE INPATIENTS IN A TERTIARY CARE HOSPITAL – AN ANALYSIS
Keerthana., S., Kulandaiammal, M., Jamila, A., & Dharani Sudha, G. (2022) · Indian Journal Of Applied Research · doi:10.36106/ijar/9802083
Preformulated, Shelf-Stable, Dendritic Cell-Targeting Nanogel mRNA Vaccine Delivery Platform
Laturski, A. E., Durán, V., Schaar, B. T., Dulay, M. T., Einav, S., & DeSimone, J. M. (2026) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6c00069
Coronavirus-19 Disease (COVID-19): Origin, Controversies, Pandemic Politics and Myths
Prabhu, S. R. (2026) · Springer eBooks · doi:10.1007/978-3-032-26000-0_1
Zember, S., Bodulić, K., Balent, N. C., Markotić, A., & Rode, O. Đ. (2026) · Vaccines · doi:10.3390/vaccines14040305
“In the pivotal trial [3] and subsequent pharmacovigilance data [19], reactogenicity increased from first to second dose, but booster studies demonstrated progressively weaker associations.”
Lafleur, B., Fung, J. S. T., Verschoor, C. P., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2368681
“30 In the same age category, 1–7% had a fever, 25–29% had a headache, and 9– 19% had joint pain.”
BackgroundPires, C. M. B. F. (2022) · Biomedical and Biopharmaceutical Research · doi:10.19277/bbr.19.1.277 · Cited by 1
de Azevedo, D. Q., Nóia, J. V. V., Ribeiro, Y. C. M., et al. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202400285
Case report of acute myocarditis after administration of coronavirus disease 2019 vaccine in Japan.
大西, 正., 田中, 妥., 杉本, 俊., et al. (n.d.) · Institutional Repositories DataBase (IRDB)
The Health and Employment Effects of Employer Vaccination MandatesPreprint
Gandhi, A. D., Larkin, I., McGarry, B. E., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5001353
Cross-national patterns of COVID-19 vaccination coverage by vaccine type
Al-Zyoud, W. A., Erekat, D., & Abudayah, M. A. (2026) · PLOS Global Public Health · doi:10.1371/journal.pgph.0006682
A biomimetic delivery strategy for achieving dual-specific lipid nanoparticle targeting
Duan, Y., Zhang, F., Guerrero, E. D., Sung, Y., Tian, Z., Wang, X., Basak, P., Chatterjee, S., Farbiak, L., & Siegwart, D. J. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100554
Liu, Z. H., Ying, Z., Shen, L., & Ma, W. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2606609123
Hesitancy of Covid-19 Vaccination among Teenagers and Young Adults
Rokkam, V. R. P. (2022) · doi:10.53902/sojmccr.2022.02.000510
Islamic Sunni perspectives on the ethics of precision medicine
Suleman, M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0017
Marumo, Y., Yoshida, T., Furukawa, Y., Ina, K., Kamiya, A., Kataoka, T., & Kayukawa, S. (2023) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2023.12.4.319
“The BNT162b2 vaccine was developed to counter https://www.ecevr.org/ https://doi.org/10.7774/cevr.2023.12.4.319 the COVID-19 pandemic, and its efficacy was confirmed in a placebo-controlled phase 3 trial [4].”
BackgroundInfluentialDid Science Leadership Fail SARS-CoV-2 Vaccination Acceptance?
McKarns, S. C. (2021) · International Journal for Innovation Education and Research · doi:10.31686/ijier.vol9.iss12.3535
Partial base pairing between 5′ and 3′ UTRs artificially regulates IVT mRNA expression levels
Hosoda, N., Takasu, A., Nakanishi, K., Hayashi, K., Saito, S., Yamada, N., & Tsuge, K. (2026) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2026.2698790
Nejad, A. S. M., Shahin-jafari, A., Abdel-Moneim, A. S., Karam, H., Ataei, B., & Ali, S. (2026) · Majallah-i dānishgāh-i ̒ulum-i pizishkī-i Kirmān. · doi:10.34172/jkmu.4195
“Vaccine efficacy is influenced by genetics, pre-existing conditions, and sex (2, 3).”
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.